On June 19, 2023, Chongqing Chemdad participated in the 21st World Pharmaceutical Ingredients China Exhibition (CPhI China) held at the Shanghai New International Expo Center. As Asia's largest pharmaceutical industry event with the highest degree of internationalization, this exhibition attracted over 3,000 enterprises and more than 55,000 professional visitors from more than 110 countries and regions worldwide.
Chongqing Chemdad's booth was located at F39-C8 in Hall E1, focusing on showcasing independently developed high-efficiency API synthesis processes and new drug delivery systems, which attracted numerous international buyers and partners. It made an appearance alongside global leading enterprises such as Pfizer and Merck.
With the theme of "Rejuvenation in All Aspects, Coming with a Fresh Look", this exhibition covered a total area of 200,000 square meters and 15 segments. In 2022, China's API export volume reached 51.79 billion US dollars, a year-on-year increase of 24%. The person in charge of Chongqing Chemdad's overseas business stated that they received customers from more than 20 countries and regions during the exhibition and reached a number of preliminary cooperation intentions.
More than 80 high-end forum activities were held during the same period of the exhibition. The technical team of Chongqing Chemdad participated in relevant seminars and salons to discuss innovative drug research and development and internationalization strategies with peers.
Chongqing Chemdad is a high-tech enterprise specializing in innovative drug research and development and production process optimization, with a number of core technology patents in the field of oncology drugs and other areas. Through this exhibition, it not only demonstrated its R&D strength but also laid the foundation for expanding the global market.